Aptose Biosciences Inc. (NASDAQ:APTO) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Aptose Biosciences Inc. (NASDAQ:APTOGet Rating) (TSE:APS) have earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $7.50.

APTO has been the topic of several research analyst reports. StockNews.com initiated coverage on shares of Aptose Biosciences in a research report on Thursday, March 31st. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Aptose Biosciences in a research note on Wednesday, March 23rd. Zacks Investment Research lowered shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Aptose Biosciences in a research note on Friday, April 1st.

Aptose Biosciences stock opened at $1.25 on Friday. Aptose Biosciences has a 1 year low of $1.00 and a 1 year high of $5.84. The firm has a market cap of $115.28 million, a price-to-earnings ratio of -1.71 and a beta of 1.50. The firm’s 50 day moving average price is $1.22 and its two-hundred day moving average price is $1.64.

Aptose Biosciences (NASDAQ:APTOGet Rating) (TSE:APS) last posted its quarterly earnings data on Tuesday, March 22nd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.09). During the same period in the previous year, the firm posted ($0.17) EPS. Analysts predict that Aptose Biosciences will post -0.69 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC lifted its stake in shares of Aptose Biosciences by 19.4% in the 1st quarter. Sanders Morris Harris LLC now owns 2,342,694 shares of the biotechnology company’s stock valued at $3,186,000 after purchasing an additional 381,100 shares during the last quarter. Virtu Financial LLC bought a new position in Aptose Biosciences in the 4th quarter worth $31,000. Millennium Management LLC raised its holdings in Aptose Biosciences by 57.6% in the 4th quarter. Millennium Management LLC now owns 1,091,222 shares of the biotechnology company’s stock worth $1,474,000 after acquiring an additional 398,691 shares during the period. Cubist Systematic Strategies LLC bought a new position in Aptose Biosciences in the 4th quarter worth $92,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Aptose Biosciences in the 4th quarter worth $357,000. 43.66% of the stock is owned by institutional investors and hedge funds.

About Aptose Biosciences (Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Stories

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.